Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
| Revenue (TTM) | $21.07B |
| Gross Profit (TTM) | $14.32B |
| EBITDA | $5.57B |
| Operating Margin | 19.10% |
| Return on Equity | 14.10% |
| Return on Assets | 5.87% |
| Revenue/Share (TTM) | $14.32 |
| Book Value | $17.68 |
| Price-to-Book | 2.52 |
| Price-to-Sales (TTM) | 2.94 |
| EV/Revenue | 3.609 |
| EV/EBITDA | 13.92 |
| Quarterly Earnings Growth (YoY) | -21.50% |
| Quarterly Revenue Growth (YoY) | 1.40% |
| Shares Outstanding | $1.45B |
| Float | $1.45B |
| % Insiders | 0.25% |
| % Institutions | 94.81% |
Volatility is currently expanding
Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.
Boston Scientific's steep valuation discount faces a major test as earnings estimates weaken, core franchises lose momentum and key growth catalysts shift to 2028.
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month primary endpoint results from the SIMPLAAFY randomized controlled trial of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
BSX, NBHC and NMRK have been added to the Zacks Rank #5 (Strong Sell) List on October 30th, 2026.
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
Boston Scientific NYSE: BSX reported third-quarter 2026 results that fell below its prior guidance after a cybersecurity incident disrupted manufacturing and product shipments for eight business days, while competitive and pricing pressures weighed on key cardiovascular franchises.
An eight-day cyber outage reduced third-quarter sales by $150 million. Management expects full-year 2026 organic revenue growth of 4%.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BSX and any ticker you trade — then tracks every position and per-strategy win rate.
